Special Issue "Zika Virus: Therapeutic Advances"

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: 31 July 2019

Special Issue Editor

Guest Editor
Dr. Juan-Carlos Saiz

Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Madrid, Spain
Website | E-Mail
Interests: Flavivirus; zoonosis; virus-host interactions; antivirals; vaccines

Special Issue Information

Dear Colleagues,

When the Zika virus (ZIKV) was first discovered in Africa in 1947, it was considered responsible for an almost negligible disease, since its infection was usually asymptomatic or produced a relatively mild illness followed by an uneventful recovery. However, after its spread in Asia in the 1980s, its subsequent outbreaks in Micronesia and French Polynesia in this century, and its recent introduction in the Americas, ZIKV now constitutes a threat to global health, causing a great social and sanitary alarm due to its association with severe neurological and ophthalmological complications. Currently, no specific vaccines or antiviral therapies against ZIKV are available, and treatments are palliative and mainly directed to symptoms relief. Nevertheless, a great effort has been made lately to search for efficient therapeutic tools (antivirals and vaccines) and to understand the involved molecular mechanisms. 

To achieve a more comprehensive understanding of the current trends in the development of new therapeutic approaches, the journal Pharmaceuticals now invites valuable contributions that report original observations or reviews on this matter.

Dr. Juan-Carlos Saiz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 850 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Zika virus
  • virus-host cell interactions
  • therapeutic
  • antivirals
  • vaccines

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Review

Open AccessReview Late Neurological Consequences of Zika Virus Infection: Risk Factors and Pharmaceutical Approaches
Pharmaceuticals 2019, 12(2), 60; https://doi.org/10.3390/ph12020060
Received: 1 March 2019 / Revised: 15 March 2019 / Accepted: 17 March 2019 / Published: 17 April 2019
PDF Full-text (654 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
Zika virus (ZIKV) infection was historically considered a disease with mild symptoms and no major consequences to human health. However, several long-term, late onset, and chronic neurological complications, both in congenitally-exposed babies and in adult patients, have been reported after ZIKV infection, especially [...] Read more.
Zika virus (ZIKV) infection was historically considered a disease with mild symptoms and no major consequences to human health. However, several long-term, late onset, and chronic neurological complications, both in congenitally-exposed babies and in adult patients, have been reported after ZIKV infection, especially after the 2015 epidemics in the American continent. The development or severity of these conditions cannot be fully predicted, but it is possible that genetic, epigenetic, and environmental factors may contribute to determine ZIKV infection outcomes. This reinforces the importance that individuals exposed to ZIKV are submitted to long-term clinical surveillance and highlights the urgent need for the development of therapeutic approaches to reduce or eliminate the neurological burden of infection. Here, we review the epidemiology of ZIKV-associated neurological complications and the role of factors that may influence disease outcome. Moreover, we discuss experimental and clinical evidence of drugs that have shown promising results in vitro or in vitro against viral replication and and/or ZIKV-induced neurotoxicity. Full article
(This article belongs to the Special Issue Zika Virus: Therapeutic Advances)
Figures

Figure 1

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top